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Umbilical Cord Blood and Type 1 Diabetes
A road ahead or dead end?
I
tisouranticipationandhopethatstem
cells will cure type 1 diabetes someday
because of their limitless capacity to
differentiateasneededintothevitaltissue
or organ.
In theory, pluripotent cells have the
capacity to reprogram a hostile immune
response to tolerate pancreatic -cells and
to regenerate pancreatic -cell mass. These
twofactorsarethenecessaryingredientsfor
reversingtype1diabetes.However,inprac-
tice there are many unanswered scientiﬁc
questions that need clariﬁcation before we
claim success.
InthisissueofDiabetesCare,Halleret
al. (1) report their interim results about
autologous umbilical cord blood infusion
into young children with type 1 diabetes.
Children aged 1 year who developed
type 1 diabetes and had banked umbilical
cord blood at an approved center were
recruited into this study at the University
of Florida. Cord blood infusion was per-
formed after the diagnosis of type 1 dia-
betes at a mean time of 4.1 months (range
2.5–7.1) and into children with a mean
age of 5.5 years (3.1–7.3). The children
werebroughtbackforclinical,metabolic,
and immunologic evaluation at 3, 6, 9,
and12monthsafterumbilicalcordblood
transfusion. Ethics considerations pre-
vented infusion of umbilical cord blood
into an age-matched nondiabetic control
group, so an age-matched group of type 1
diabetic subjects was used for compari-
son. This constraint, although subopti-
mal, will be necessary in future stem cell
type 1 diabetes trials but should not sig-
niﬁcantlycompromiseourabilitytointer-
pret the study outcomes.
The results of the present study are
uniformly negative; umbilical cord blood
infusion failed to improve C-peptide, in-
sulin utilization, and A1C and did not in-
creaseregulatoryT-cell(Treg)levelsat12
months. Assuming that the 24-month re-
sults will also fail to demonstrate efﬁcacy
in curing or ameliorating type 1 diabetes,
how do we navigate the clinical complex-
ities of stem cell trials for type 1 diabetes?
Not only are there several potential cell
sources that might be used for type 1 di-
abetes (e.g., mesenchymal stem cells, he-
matopoetic stem cells, adipose-derived
stem cells, and umbilical cord blood), but
we must also identify the appropriate con-
ditions for expanding these cells, selecting
theappropriatesubpopulationsofcells,and
administering the proper cell dose.
The rationale for testing umbilical
cord blood in young children with type 1
diabetes is primarily related to safety. In-
deed, the results to date suggest that um-
bilical cord blood infusion is without side
effects and can be given safely to children
with type 1 diabetes. The matter of efﬁ-
cacy is more problematic. The present
studygivesusastrongnegativesignalthat
simple umbilical cord blood infusion
might not provide a road forward toward
curing type 1 diabetes. Two important
considerations need to be resolved before
we can reach this ﬁnal conclusion: 1) the
dose of umbilical cord blood in this study
might be suboptimal to reverse type 1 di-
abetes and 2) a transient rise in Tregs
bearing CD4
CD25
 surface markers
was observed at 6 months after umbilical
cord blood but not at 12 months. These
two issues are interrelated because a sub-
optimal dose of umbilical cord blood
might provide neither the critical mass of
Tregs to control autoimmunity nor the
requisite number of stem cells to increase
pancreatic -cell mass. Improvements in
cryopreservation techniques and expan-
sion of umbilical cord blood stem cells
prior to therapeutic infusion might over-
come these problems in the future.
Although at present we have no road-
map for the use of stem cells to reverse
type 1 diabetes in children, two promis-
ing research discoveries might provide us
with clues for future clinical trials. Re-
cently, Zhao et al. (2,3) used human um-
bilical cord blood stem cells to reverse
type 1 diabetes in nonobese diabetic
(NOD) mice. These investigators devel-
oped coculture techniques by mixing
nondiabetic human umbilical cord blood
stem cells with NOD mouse spleen cells
to generate an unconventional subset of
Tregs bearing CD4
CD62L
 but not
CD25
on the cell surface. These uncon-
ventional Tregs, when injected into dia-
betic NOD mice, reversed type 1 diabetes
75% of the time and stimulated pancre-
atic -cell regeneration. Conventional
TregsbearingCD4
CD25
FoxP3
(note
FoxP3 is a transcription factor that de-
marcates functional Tregs) did not pos-
sess these regenerative properties. These
unconventional CD4
CD62L
 cells
could only be derived using puriﬁed hu-
man cord blood stem cells from healthy
donors but not from type 1 diabetes do-
nors (Y. Zhao, personal communication).
Apparently, healthy umbilical cord blood
possesses a critical stem cell population
capable of reeducating and transforming
diabetic regulatory cells into regenerative
CD4
CD62L
 cells capable of reversing
type 1 diabetes. Conversely, umbilical
cord blood obtained from individuals
who later developed type 1 diabetes does
not contain this critical stem cell popula-
tion and therefore might not be a useful
source of regenerative cells. Although
there is danger in extrapolating insights
gained from studies in NOD mice to chil-
dren with type 1 diabetes, this neverthe-
less might explain why the present study
has failed so far. Maybe conventional
Tregs bearing CD4
CD25
 on their cell
surface are the wrong regenerative cell
population? In addition, Bluestone and
colleagues (4) demonstrated that conven-
tional polyclonal CD4
CD25
 Tregs
were minimally effective at reversing type
1 diabetes in NOD mice, but puriﬁed an-
tigen-speciﬁc CD4
CD25
 T-cells re-
versed type 1 diabetes in 60% of NOD
mice. Here also, if we permit extrapola-
tion from mouse to human, we encounter
a potential problem with umbilical cord
blood infusion in type 1 diabetic children
because umbilical cord blood cells con-
tain primarily polyclonal Tregs. Future
stem cell trials for children with type 1
diabetes will inevitably lean on discover-
ies made in rodent models of the disease,
inherent limitations notwithstanding. It
behooves us to use our translational sci-
ence wisely to sort out the limitless vari-
ables that are likely to complicate human
stem cell trials for type 1 diabetes.
In summary, the present study using
umbilical cord blood infusion in children
with newly diagnosed type 1 diabetes has
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about the safety of such a therapy. Un-
fortunately, it does not move us very far
forward in discovering an efﬁcacious
therapy to reverse type 1 diabetes. By in-
tegrating new information from the labo-
ratory into clinical trial design, we can
hopefullyshortcuttheroadtocuringtype
1 diabetes with stem cells. Otherwise, we
may travel down many dead ends before
we ﬁnd a road ahead.
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